Effect of Xuesaitong Soft Capsule (血塞通软胶囊) on Hemorrheology and in Auxiliarily Treating Patients with Acute Cerebral Infarction

Objective: To observe the therapeutic effect of Xuesaitong soft capsule(血塞通软胶囊, XST)and its effect on platelet counts, coagulation factor 1 (CF1) as well as hemorrheologic indexes in treating patients with acute cerebral infarction (ACI). Methods: Two hundred and four patients with ACI were assigned into two groups, the control group (n=96) and the treated group (n=108). They were all treated with conventional Western medicines, including mannitol, troxerutin, citicoline, piracetam and aspirin, while to the treated group, XST was given additionally through oral intake, twice a day, 2 capsules each time for 8 successive weeks. The clinical efficacy was evaluated according to the nerve function deficits scoring and the changes of platelet count. CF1 and hemorrheological indexes were measured before and after treatment.Results: The total effective rate was 87.0% in the treated group, and 87.5% in the control group, respectively, showing insignificant difference between them. But the markedly effective rate in the treated group ( 66.7%) was significantly higher than that in the control group (27.1%, P<0.01). The count of platelet was not changed significantly in both groups after treatment, while CF1 in them evidently lowered at the end of the 4th and 8th weeks of treatment, but showed insignificant difference between the two groups. The hematocrit, whole blood viscosity and plasma viscosity in both groups were all improved significantly after treatment, but also showed insignificant difference in comparison of the two groups. Conclusion: XST has good efficacy in auxiliary treatment of patients with ACI, though its mechanism remains to be further explored.

Effects of Hemp seed soft capsule on colonic ion transport in rats

AIM To investigate the effect of Hemp seed soft capsule(HSCC) on colonic ion transport and its related mechanisms in constipation rats.METHODS Sprague-Dawley male rats were randomly divided into three groups: normal group, constipation group and HSSC group. Rats in the constipation and HSSC groups were administrated loperamide 3 mg/kg per day orally for 12 d to induce the constipation model. Then, the HSSC group was given HSSC 0.126 g/kg per day by gavage for 7 d. The normal and constipation groups were treated with distilled water. After the treatment, the fecal wet weight and water content were measured. The basal short-circuit current(Isc) and resistance were measured by an Ussing Chamber. Besides the in vivo drug delivery experiment above, an in vitro drug application experiment was also conducted. The accumulative concentrations of HSSC(0.1 mg/m L, 0.5 mg/m L, 1.0 mg/m L, 2.5 mg/m L, 5.0 mg/m L, 10.0 mg/m L and 25.0 mg/m L) were added to the normal isolatedcolonic mucosa and the Isc was recorded. Further, after the application of either ion(Cl^-or HCO_3^-) substitution, ion channel-related inhibitor(N-phenylanthranilic acid, glybenclamide, 4,4-diisothiocyano-2,2-stilbenedisulfonic acid or bumetanide) or neural pathway inhibitor [tetrodotoxin(TTX), atropine, or hexamethonium], the Isc induced by HSSC was also measured. RESULTS In the constipation group, the fecal wet weight and the water content were decreased in comparison with the normal group(P < 0.01). After the treatment with HSSC, the fecal wet weight and the water content in the HSSC group were increased, compared with the constipation group(P < 0.01). In the constipation group, the basal Isc was decreased and resistance was increased, in comparison with the normal group(P < 0.01). After the treatment with HSSC, the basal Isc was increased(P < 0.05) and resistance was decreased(P < 0.01) in the HSSC group compared with the constipation group. In the in vitro experiment, beginning with the concentration of 1.0 mg/m L, differences in Isc were found between the experimental mucosa(with HSSC added) and control mucosa. The Isc of experimental mucosa was higher than that of control mucosa under the same concentration(1.0 mg/m L, P < 0.05; 2.5-25 mg/m L, P < 0.01). After the Cl^-or HCO_3^-removal and pretreated with different inhibitors(c AMPdependent and Ca^(2+)-dependent Cl^-channels, Na^+-K^+-2 Cl^-cotransporter(NKCC), Na^+-HCO_3^-cotransporter or Cl^-/HCO_3^-exchanger inhibitor), there were differences between experimental mucosa and control mucosa; the Isc of experimental mucosa was lower than that of control mucosa under the same concentration(P < 0.05). Meanwhile, after pretreatment with neural pathway inhibitor(TTX, atropine, or hexamethonium), there were no differences between experimental mucosa and control mucosa under the same concentration(P > 0.05).CONCLUSION HSSC ameliorates constipation by increasing colonic secretion, which is mediated via the coaction of c AMPdependent and Ca^(2+)-dependent Cl^-channels, NKCC, Na^+-HCO_3^-cotransporter or Cl^-/HCO_3^-exchanger.

Clinical Observation of the Effect of Xuesaitong Soft Capsule (血塞通软胶囊) on Post-hepatitis Fibrosis

Objective: To study the effect of Xuesaitong soft capsule (血塞通软胶囊, XST) on liver fibrosis criteria in patients with post-hepatitis fibrosis. Methods: Sixty-four patients with such fibrosis were randomly divided into the treated group and control group. They were treated with XST and Dahuang Zhechong pill (大黄NFDA1虫丸) for 3 months respectively. Their liver fibrosis criteria were examined before and after treatment. Results: The levels of serum procollagen Ⅲ, hyaluronic acid, collagen Ⅳ, laminin in the two groups were significantly lower ( P <0.01) than those before treatment. The differences between the two groups were insignificant ( P >0.05). Conclusion: XST could recover liver dysfunction and had anti-liver fibrosis function.

Study of Interference Treatment by Xuesaitong (血塞通) Soft Capsuleon Patients of Nephrosis Syndrome with Qi Deficiency and Blood Stasisduring Dose Reducing Stage of Corticosteroid

Objective: To observe the effect of Xuesaitong (血塞通, XST) soft capsule in interference treatment on patients of nephrosis syndrome (NS) during corticosteroid (CS) dose reducing stage. Methods: Seventy-one NS patients applying prednisone and initiating dose reducing stage were randomized into trial group and control group. On the basis of conventional prednisone dose reduction of both groups, the trial group was given additionally XST, and the treatment course ended with the reduction to maintenance dose. In the course of observation, those who did not comply with the criteria of observation were excluded. Before and after the dose reduction, TCM syndrome scoring, 24 hrs urinary protein amount, blood β2-microglobulin (β2-MG), urinary β2-MG, blood fibrinogen (Fbg), plasma prothrombin time (PT), blood lipid, etc. were observed. Results: The trial group of XST could obviously lower their urinary protein amount and blood lipid level (P<0.05 or P<0.01), markedly improve the blood coagulation parameters (P<0.01), improve the TCM syndrome and CS induced adverse reaction (P<0.05 or P<0.01), also obviously reduced the recurrence rate of NS (P<0.05). Conclusion: XST could obviously improve the clinical symptoms and renal impairment parameters in NS patients during CS dose reduction stage, improve the CS induced adverse reaction and prevent the recurrence of NS.

Influence of Yishen Guben Qutong decoction combined with menatetrenone soft capsule on bone metabolism,bone conversion index and clinical efficacy in osteoporosis patients

Objective:To observe the effect of tetradecylene naphthalene soft capsule combined with Yishen Gubenyutong Decoction on bone metabolism and bone turnover in patients with osteoporosis and its clinical efficacy.Methods:A total of 100 patients with primary osteoporosis(all were treated by our hospital from February 2017 to June 2018)were divided into two groups.The control group(50 cases)was given to menatetrenone capsules.Treatment,observation group(50 cases)combined with Yishen Gubenqiaotongtong on the basis of the treatment of the control group,6 months for a course of treatment.The bone metabolic markers,bone mineral density changes and clinical efficacy were measured before and after treatment.Results:The total effective rate of the observation group was higher than that of the control group.After treatment,the observation group showed serum calcium(Ca),serum alkaline phosphatase(ALP)and typeⅠcollagen.The level of cross-linked C-terminal peptide(CTX-1)was lower than that of the control group.After treatment,the osteocalcin(OC)in the observation group was higher than that in the control group,and the bone mineral density(BMD)of lumbar vertebrae L2-4,femoral neck and femur trochanter in the observation group were higher than those in the control group.Conclusion:Menatetrenone soft capsule combined with Yishen Gubenyutong Decoction has good clinical effect on osteoporosis patients and it is worth further promotion in clinic.

HPLC Study on HPLC Characteristic Spectrum of Huoxiang(Herba Agastachis)Eliminating Summer-heat Soft Capsule

To establish HPLC characteristic spectrum of Huoxiang(Herba Agastachis)Eliminating Summer-heat Soft Capsule.Chromatographic separation was performed on Tech Mate C18-ST(5 um,4.6×250 nm)column by Agilent 1260 high performance liquid chromatograph,eluted with acetonitrile and 0.05%phosphoric acid in a gradient elution at a flow rate of 1.0 mL∙min-1.The detection wavelength was set at 270 nm.Hesperidin was selected as the reference peak to calculate the RSD of the relative retention time.Precision,stability and reproducibility were investigated as well.80 different samples from 5 manufacturers were included in this study.The HPLC characteristic spectrum of Huoxiang Eliminating Summer-heat Soft Capsule was constructed with 11 specific chromatographic peaks in 80 samples.The method is accurate,reliable and with good reproducibility,and could overall control the quality of Huoxiang Eliminating Summerheat Soft Capsule.

Effect of Dan seven soft capsule adjuvant therapy on serum inflammatory factors, coagulation function and blood rheology indexes in patients with acute hemorrhagic cerebrovascular disease

Objective: To investigate the effect of Dan seven soft capsule on the treatment of acute hemorrhagic cerebrovascular disease and the influence of serum inflammatory factors, coagulation function and blood rheology indexes. Methods: A total of 112 cases of patients with acute hemorrhagic cerebrovascular disease, according to the random data table were divided into the control group (n=57) and observation group (n=55), the patients in the control group received routine treatment combined with edaravone, on the basis of the treatment of the control group, the observation group was treated with Dan seven soft capsule. The serum levels of inflammatory factors, coagulation function and blood rheology indexes were compared between the two groups before and after treatment. Results: Before treatment, there were no significant difference in the inflammatory factors (hs-CRP, TNF-α and IL-6), blood coagulation function (FIB, PT and APTT) and hemorheology (high cut whole blood viscosity, low cut whole blood viscosity and plasma viscosity) levels between the control group and observation group. Compared with the levels of the same group before treatment, two groups of hs-CRP, TNF-α, IL-6, FIB, high cut whole blood viscosity, low cut whole blood viscosity and plasma viscosity level after treatment were significantly decreased, and levels in the observation group were significantly lower than those in the control group;Compared with the group before treatment, the levels of PT and APTT in the two groups were significantly increased, and the observation group was significantly higher than the control group. Conclusion: Dan seven soft capsule in the treatment of acute hemorrhagic cerebrovascular disease can effectively reduce the level of serum inflammatory factors, improve coagulation function and blood rheology index, it has an important clinical value.

依帕司他联合丁苯酞软胶囊对痛性糖尿病周围神经病变患者的影响

目的:分析依帕司他联合丁苯酞软胶囊对痛性糖尿病周围神经病变(PDPN)患者的影响。方法:选取2021年2月—2022年2月通城县人民医院收治的80例PDPN患者作为研究对象,根据掷硬币法将患者分为对照组和研究组,各40例。对照组给予依帕司他,研究组在对照组基础上给予丁苯酞软胶囊,比较两组临床疗效、不良反应、疼痛程度[视觉模拟评分法(VAS)]、正中神经、腓总神经、尺神经的感觉神经传导速度(SNCV)、运动神经传导速度(MNCV)及氧化应激指标[超氧化物歧化酶(SOD),丙二醛(MDA)]水平。结果:研究组临床总有效率高于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05);治疗1个月后,两组VAS评分低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);治疗1个月后,两组正中神经、腓总神经、尺神经的SNCV和MNCV较治疗前提高,且研究组高于对照组,差异有统计学意义(P<0.05);治疗1个月后,两组SOD和MDA水平较治疗前改善,且研究组SOD水平高于对照组,MDA水平低于对照组,差异有统计学意义(P<0.05)。结论:依帕司他与丁苯酞软胶囊联合治疗PNDN,临床疗效好,不良反应发生率较低,能显著降低疼痛程度,提高正中神经、腓总神经、尺神经SNCV和MNCV,改善SOD和MDA水平。

地奥心血康软胶囊联合沙库巴曲缬沙坦治疗缺血性心肌病的疗效及对心室重构、生存质量的影响

目的探讨地奥心血康软胶囊联合沙库巴曲缬沙坦治疗缺血性心肌病的疗效及对心室重构、生存质量的影响。方法回顾性选取2018年9月到2023年9月滁州市中西医结合医院收治的80例缺血性心肌病患者,依据治疗方法的不同将其分为对照组与观察组,每组各40例。对照组应用沙库巴曲缬沙坦治疗,观察组应用地奥心血康软胶囊联合沙库巴曲缬沙坦治疗。治疗3个月后,比较两组患者临床疗效,比较两组患者治疗前、治疗3个月后的血液生化指标[B型脑钠肽(BNP)、高敏C反应蛋白(hs-CPP)、超氧化物歧化酶(SOD)]、Killip心功能分级、心室重构相关指标[左心室重构指数(LVRI)、左心室质量指数(LVMI)]水平,以及明尼苏达心力衰竭生存质量问卷(MLHFQ)评分。结果治疗3个月后,观察组治疗总有效率为95.00%,高于对照组(75.00%),差异有统计学意义(P<0.05)。治疗3个月后,两组患者BNP、hs-CPP水平均较治疗前降低,SOD水平均较治疗前升高,且观察组BNP、hs-CPP水平分别为(93.28±8.62)pg/L、(29.12±4.12)mg/L,均明显低于对照组[(125.61±10.69)pg/L、(37.12±4.25)mg/L],SOD水平为(108.27±10.69)nU/mL,高于对照组[(93.67±15.45)nU/mL],差异均有统计学意义(P<0.05)。观察组治疗3个月后,患者Ⅰ级比率为47.50%,高于对照组(25.00%),Ⅲ级、Ⅳ级比率为7.50%、0,明显低于对照组(25.00%、10.00%),差异均有统计学意义(P<0.05)。观察组LVRI、LVMI为(2.52±0.43)g/mL、(93.43±7.17)g/m^(2),均低于对照组[(2.94±0.24)g/mL、(110.31±11.28)g/m^(2)],差异有统计学意义(P<0.05)。治疗3个月后,两组患者MLHFQ中身体领域、情绪领域、其他领域各分值及MLHFQ总分均较治疗前升高,且观察组身体领域、情绪领域、其他领域各分值及MLHFQ总分分别为(32.56±7.11)、(20.36±4.25)、(33.93±5.13)、(86.87±8.37)分,均高于对照组[(27.87±5.13)、(17.56±4.46)、(30.01±4.05)、(75.44±5.66)分],差异均有统计学意义(P<0.05)。结论地奥心血康软胶囊联合沙库巴曲缬沙坦治疗缺血性心肌病临床疗效显著,可降低BNP表达水平,同时能够抑制脂质过氧化反应,减轻机体炎症反应水平,提升心功能,改善心室重构情况,进而提升患者生存质量。

黄体酮软胶囊不同给药方案用于激素替代冻融胚胎移植黄体支持的临床结局比较

目的比较黄体酮软胶囊不同给药方案进行激素替代冻融胚胎移植中黄体支持的临床疗效。方法对2019年1月至2021年12月期间在中南大学湘雅医院生殖中心行激素替代冻融胚胎移植的3845例患者临床数据进行回顾性分析,纳入的所有患者黄体支持均采用阴道用黄体酮软胶囊联合口服地屈孕酮治疗,根据阴道用黄体酮软胶囊不同用法将其划分为两组:A组每次使用200 mg,每日3次,共1858个周期;B组每次使用300 mg,每日2次,共1987个周期,评估两组的临床治疗效果。结果两组患者在年龄、不孕年限、体质量指数(BMI)、转化日子宫内膜厚度、转化日雌激素(E_(2))水平、转化日孕激素(P)水平、移植优胚占比等方面比较均无显著差异(P>0.05)。A、B两组患者的活产率分别是34.71%(645/1858)和36.39%(723/1987),而移植囊胚的临床妊娠率分别为52.3%(182/348)和55.37%(397/717),两组间比较均无显著性差异(P>0.05)。人绒毛膜促性腺激素(HCG)阳性率、流产率和异位妊娠率等两组间比较也均无显著性差异(P>0.05)。结论冻融胚胎移植激素替代周期中,采用两种不同剂量不同频次的阴道用黄体酮软胶囊治疗作为黄体支持,能够达到相似的临床疗效。

交叉融合探索性实验在食品营养与健康专业教学中的应用

依托华南理工大学食品科学与工程学院优质科研资源和实验条件,为新设立的食品营养与健康专业开设不同功效成分软胶囊生产和质量检测实验课。该课程为综合性探索性实验,融合食品专业多学科知识,采用学生为主体、教师指导的开放式教学模式,学生分组合作,包括设计配方、生产、包装、质量检测和撰写报告。实验内容贴合日常保健和健康,涵盖知识点多,可操作性强,能极大激发学生的实验兴趣和培养综合能力。两年的教学实践表明,教学效果反馈良好,学生认可度高。

丁苯酞软胶囊治疗颈动脉粥样硬化患者作用分析

目的观察丁苯酞软胶囊治疗颈动脉粥样硬化患者的效果。方法回顾性选取2021年9月—2023年2月泰安市中医医院接收的80例颈动脉粥样硬化患者的临床资料,以治疗方法的不同将患者分为对照组(n=40,阿托伐他汀治疗)和观察组(n=40,加用丁苯酞软胶囊治疗),比较两组治疗的效果。结果观察组的临床总有效率为97.50%,高于对照组的80.00%,差异有统计学意义(χ^(2)=4.507,P<0.05)。治疗前,两组的斑块数量、颈动脉内膜中层厚度(Intima-media Thickness,IMT)以及斑块面积对比,差异无统计学意义(P均>0.05);治疗后,观察组斑块数量、IMT以及斑块面积低于对照组,差异有统计学意义(P均<0.05)。治疗前,两组的血清淀粉样蛋白A(Serum Amyloid A,SAA)、白细胞介素-1β(Interleukin-1β,IL-1β)以及白细胞介素-6(Interleukin-6,IL-6)对比,差异无统计学意义(P均>0.05);治疗后,观察组SAA、IL-1β以及IL-6低于对照组,差异有统计学意义(P均<0.05)。对照组与观察组的不良反应发生率分别为10.00%与7.50%,差异无统计学意义(P>0.05)。结论在阿托伐他汀的基础上加用丁苯酞软胶囊治疗颈动脉粥样硬化的效果较为明显,同时可以减少斑块数量、IMT以及斑块面积,并且降低炎症因子水平,安全性较好。

中风活心软胶囊通过靶向微小RNA-126诱导缺氧诱导因子-1α/促凋亡调节蛋白BNIP3信号通路促进自噬减轻脑缺血再灌注损伤大鼠神经损伤的作用机制研究

目的探讨中风活心软胶囊通过靶向微小RNA(miRNA)-126诱导缺氧诱导因子-1α(HIF-1α)/促凋亡调节蛋白BNIP3信号通路促进自噬减轻脑缺血再灌注损伤大鼠神经损伤的作用机制。方法选取30只无特定病原体(SPF)级雄性SD大鼠,随机分为空白组、模型组与治疗组,每组10只。采用Zea Longa法建立右侧大脑中动脉缺血(MCAO)大鼠模型。治疗组给予中风活心软胶囊。采用改良神经功能损害评分(mNSS)评估大鼠神经功能缺损情况,透射电镜观察缺血半暗区皮质神经元及自噬囊泡超微结构,蛋白质免疫印迹(WB)法和实时荧光定量聚合酶链式反应(RT-qPCR)法分别检测缺血半暗区皮质雷帕霉素靶蛋白(mTOR)、HIF-1α蛋白及其mRNA和miR-126的表达水平。结果模型组、治疗组mNSS评分均高于对照组,但治疗组低于模型组,差异有统计学意义(P<0.05)。模型组、治疗组缺血半暗区皮质mTOR、HIF-1α蛋白表达水平均高于对照组,但治疗组低于模型组,差异有统计学意义(P<0.05)。模型组、治疗组缺血半暗区皮质mTOR、HIF-1αmRNA表达水平均高于对照组,miR-126表达水平低于对照组,但治疗组mTOR、HIF-1αmRNA表达水平低于模型组,miR-126表达水平高于模型组,差异有统计学意义(P<0.05)。治疗组缺血半暗区皮质神经元及电镜下自噬囊泡数量明显增加,细胞结构损坏减轻。结论中风活心软胶囊可显著提高脑缺血大鼠缺血半暗区皮质mTOR、HIF-1α因子表达,其作用机制可能是通过激活miR-126表达进而靶向调控mTOR/HIF-1α信号通路,促进自噬,从而发挥其脑保护效应。

地奥心血康软胶囊联合依那普利对冠心病合并心房颤动患者血压测量波动性的影响

目的:探讨地奥心血康软胶囊联合依那普利对冠心病合并心房颤动患者血压测量波动性的影响。方法:选取2021年1月~2021年10月就诊于九江市第一人民医院的136例冠心病合并持续性非瓣膜性心房颤动患者,计算分析包括年龄、性别、合并疾病、合并用药等参数在内的各项因素和血压波动的相关性,并就是否联合使用地奥心血康软胶囊在管理血压波动方面的价值进行探索。结果:年龄、性别、合并疾病(高血压、糖尿病、卒中、心力衰竭、高脂血症)、合并用药[血管紧张素转化酶抑制剂(ACEI)、血管紧张素受体拮抗剂(ARB)、β受体阻滞剂、钙离子通道阻滞剂(CCB)、利尿剂、抗凝药、抗血小板药、他汀]与基线水平血压波动之间的相关性差异无统计学意义(P>0.05);在将计算血压波动结点值设置为“6 mmHg”这一前提下,总体研究对象的血压波动达标率为29.4%,联药组在随访过程中的血压波动达标率呈逐渐上升趋势,单药组的血压波动达标率也呈现了波动性,单药组对应时间节点的血压波动达标率较之于联药组均偏低。结论:地奥心血康软胶囊与血压管理具有良好的相关性且能够降低血压的波动性,可以考虑联合依那普利作为降压控压方案。

观察硫酸氢氯吡格雷片联合丁苯酞软胶囊治疗脑梗死的疗效及对其血清特异性指标的影响

目的探究硫酸氢氯吡格雷片联合丁苯酞软胶囊治疗脑梗死的疗效及对其血清特异性指标的影响,以丰富临床的理论依据。方法80例脑梗死患者,以随机平行对照法分成对照组(40例)和观察组(40例)。对照组采取硫酸氢氯吡格雷片治疗,观察组采取硫酸氢氯吡格雷片联合丁苯酞软胶囊治疗。比较两组血清特异性指标(血清S100-β蛋白、CD40L)、脑循环血量参数(脑血管平均血流速度、血管外周阻力、血管特性阻抗)、神经营养[脑源性神经营养因子(BDNF)、神经生长因子(NGF)]水平、生活质量[脑卒中专用生活质量量表(SS-QOL)评分]及临床效果。结果观察组治疗总有效率90.00%比对照组的72.50%更高(P<0.05)。两组治疗后血清S100-β蛋白、CD40L水平比本组治疗前更低,且观察组血清S100-β蛋白(0.23±0.05)ng/ml、CD40L(9.69±1.34)μg/L比对照组的(0.41±0.12)ng/ml、(11.57±2.01)μg/L更低(P<0.05)。两组治疗后脑血管平均血流速度比本组治疗前更高,血管外周阻力、血管特性阻抗比本组治疗前更低,且观察组脑血管平均血流速度(11.60±5.22)cm/s高于对照组的(8.89±4.73)cm/s,血管外周阻力(2367.31±129.16)BSA、血管特性阻抗(3017.83±136.95)dyn·s/cm^(5)低于对照组的(2861.42±137.20)BSA、(4089.35±160.74)dyn·s/cm^(5)(P<0.05)。两组治疗后血清BDNF、NGF水平比本组治疗前更高,且观察组血清BDNF(4.35±0.83)ng/ml、NGF(138.36±18.92)pg/ml比对照组的(3.17±0.72)ng/ml、(126.53±19.09)pg/ml更高(P<0.05)。两组治疗后SS-QOL体能、活动能力、自理、社会角色、上肢功能、工作能力评分比本组治疗前更高,且观察组SS-QOL体能、活动能力、自理、社会角色、上肢功能、工作能力评分比对照组更高(P<0.05)。结论硫酸氢氯吡格雷片联合丁苯酞软胶囊可作为脑梗死疾病的有效治疗方案,其能够改善患者血清特异性指标的异常水平,提高神经营养水平,促进脑部血液循环,有助于早日康复。

银丹心脑通软胶囊联合静脉溶栓治疗急性缺血性脑卒中的临床疗效

目的:探讨银丹心脑通软胶囊联合静脉溶栓治疗急性缺血性脑卒中(AIS)患者的临床疗效。方法:选取2022年1月-2023年1月徐州市第一人民医院收治的AIS患者80例为研究对象,根据随机数字表法分为对照组和研究组,各40例。对照组给予静脉溶栓治疗,观察组给予银丹心脑通软胶囊联合静脉溶栓治疗。比较两组患者临床效果。结果:研究组治疗总有效率高于对照组,差异有统计学意义(P=0.004);治疗后,两组甘油三酯、总胆固醇、低密度脂蛋白胆固醇水平均降低,研究组低于对照组,两组高密度脂蛋白胆固醇水平均升高,研究组高于对照组,差异有统计学意义(P<0.05);治疗后,两组活化部分凝血酶时间、凝血酶原时间水平均降低,研究组低于对照组,两组纤维蛋白原、D-二聚体水平均升高,研究组高于对照组,差异有统计学意义(P<0.05);治疗后,两组卒中量表、Rankin修订总评分均降低,研究组低于对照组,差异有统计学意义(P<0.05)。结论:AIS患者采用银丹心脑通软胶囊联合静脉溶栓治疗效果显著,可改善患者神经功能缺损、病残程度、血脂水平及凝血功能。

醒脑静联合丁苯酞治疗急性脑梗死的疗效观察及对血液流变学、外周血IL-23、MIP-1α水平的影响

目的:研究醒脑静注射液联合丁苯酞软胶囊治疗急性脑梗死(ACI)的疗效,以及对血液流变学、外周血白细胞介素-23(IL-23)、巨噬细胞炎性蛋白-1α(MIP-1α)水平的影响。方法:按随机数字表法将2018年7月—2022年7月河南科技大学第一附属医院诊治的ACI患者106例分为2组,各53例。对照组口服丁苯酞软胶囊,观察组采用丁苯酞软胶囊联合醒脑静注射液治疗。比较2组治疗后的临床疗效、治疗前后美国国立卫生研究院卒中量表(NIHSS)评分、血液流变学指标、外周血IL-23和MIP-1α水平等。结果:治疗后,观察组总有效率为94.34%,高于对照组的79.25%(P<0.05);2组NIHSS评分均较干预前明显降低,且观察组低于对照组,差异均有统计学意义(P<0.05);2组血浆黏度(PV)、纤维蛋白原(FIB)、血细胞比容(HCT)均较干预前明显降低,且观察组低于对照组,差异均有统计学意义(P<0.05);2组IL-23、MIP-1α水平均较干预前明显降低,且观察组低于对照组,差异均有统计学意义(P<0.05)。结论:醒脑静注射液联合丁苯酞软胶囊对ACI患者有较好疗效,能明显降低NIHSS评分,调节血液流变学指标,降低外周血IL-23、MIP-1α水平。

甲硝唑、硝呋太尔制霉素阴道软胶囊、乳酸菌阴道胶囊联合治疗细菌性阴道炎的临床效果分析

目的 探讨三联用药方案(甲硝唑+硝呋太尔制霉菌素阴道软胶囊+乳酸菌阴道胶囊)对细菌性阴道炎(bacterial vaginosis, BV)患者的疗效。方法 方便选取2021年8月—2023年12月济南市第一人民医院收治的66例BV患者为研究对象,按照不同治疗方法分为两组,各33例。对照组予以甲硝唑、硝呋太尔制霉菌素软胶囊干预;研究组除了给予上述药物外,加用乳酸菌阴道胶囊干预。比较两组的临床疗效、阴道内环境及不良反应。结果 研究组治疗总有效率为96.97%(32/33),高于对照组的78.79%(26/33),差异有统计学意义(χ^(2)=5.121,P=0.024)。用药后,研究组乳酸杆菌、葡萄球菌、类杆菌、pH检验结果优于对照组,差异有统计学意义(P均<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论 3种药物联用,对于BV不仅有较好的效果且安全性均较优,有利于提高患者阴道内环境改善效果。

增液八珍汤在老年习惯性便秘患者中的应用价值探讨

目的探讨增液八珍汤在老年习惯性便秘患者中的应用价值。方法回顾性选取2020年6月—2023年6月南京中医药大学附属徐州市中医院收治的86例老年习惯性便秘患者的临床资料,按照给药方式不同分为对照组和观察组。对照组31例,给予麻仁软胶囊;观察组55例,给予麻仁软胶囊与增液八珍汤。对比两组患者治疗有效率、临床症状、生活质量。结果观察组临床总有效率为94.55%(52/55),高于对照组的67.74%(21/31),差异有统计学意义(χ^(2)=5.694,P<0.05);治疗后,观察组每周排便次数(4.29±0.25)次、排便时间(8.46±0.64)min均优于对照组的(3.61±0.21)次、(13.58±1.02)min;观察组大便性状(2.31±0.17)分优于对照组的(2.85±0.16)分,差异有统计学意义(t=12.803、23.674、14.441,P均<0.05);治疗后,观察组生活质量评分为(86.53±3.99)分,优于对照组的(73.95±2.85)分,差异有统计学意义(t=15.455,P<0.05)。结论在麻仁软胶囊治疗的基础上加用增液八珍汤可显著提高老年习惯性便秘患者的治疗效果和生活质量,可有效改善临床症状。

亚麻籽油磷虾油软胶囊对高血脂模型大鼠血脂的影响

为研究亚麻籽油磷虾油软胶囊对高血脂的缓解功效,将50只雄性大鼠随机分为5组,高脂饲料造模7 d,经口给予大鼠不同剂量的亚麻籽油磷虾油软胶囊内容物30 d。通过检测各组大鼠血清中甘油三酯(triglyceride,TG)、总胆固醇(total cholesterol,TC)、低密度脂蛋白胆固醇(low density lipoprotein cholesterol,LDL-C)和高密度脂蛋白胆固醇(high density lipoprotein cholesterol,HDL-C)指标,评价亚麻籽油磷虾油软胶囊辅助降血脂的功效。结果显示:与空白对照组比较,模型组血清中TC、TG、LDL-C均极显著升高(P<0.01),说明模型成立;与模型对照组相比,低、高剂量组大鼠TC含量显著降低(P<0.05),分别降低了13.73%和14.79%;各剂量组大鼠TG、LDL-C含量均显著降低,TG分别降低了45.87%、55.44%和64.03%,LDL-C分别降低了40.54%、26.12%和46.85%,各剂量组大鼠体重及HDL-C无显著性差异,表明亚麻籽油磷虾油软胶囊具有辅助降血脂的功效。